NASDAQ: CABRCaring Brands Inc Stock
$1.35-0.07 (-4.93%)
Updated Jul 2, 2026
CABR Price
$1.35
Fair Value Price
$0.15
Market Cap
$12.27M
52 Week Low
$0.71
52 Week High
$3.20
P/E
N/A
P/B
-6.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.19
Operating Cash Flow
N/A
Beta
1.55
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CABR Overview
Caring Brands, Inc. operates as a consumer wellness company, offering a varied collection of over-the-counter (OTC) and cosmetic merchandise. Its extensive product catalog features items such as hair loss treatments, solutions for eczema and psoriasis, vitiligo remedies, a specialized sun protection line that defends against jellyfish stings, and intimate health products for women. All these offerings are crafted to fulfill a wide array of health and personal care requirements. The firm was founded in 2020 and is based in Jupiter, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CABR's potential to beat the market
- CABR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
CABR
RankedUnranked of 51
RankedUnranked of 51
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $174.26 | A | |
| $39.80 | A | |
| $4.33 | A |
Be the first to know about important CABR news, forecast changes, insider trades & much more!
CABR News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CABR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CABR ($1.35) is overvalued by 810.74% relative to our estimate of its Fair Value price of $0.15 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CABR ($1.35) is not significantly undervalued (810.74%) relative to our estimate of its Fair Value price of $0.15 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CABR's short-term assets ($2.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more CABR due diligence checks available for Premium users.
Valuation
CABR fair value
Fair Value of CABR stock based on Discounted Cash Flow (DCF)
Price
$1.35
Fair Value
$0.15
Overvalued by
810.74%
CABR ($1.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CABR ($1.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CABR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-5.68x
Market
8.54x
CABR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.13x
Industry
1.59x
CABR's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
Assets to liabilities
Assets
$2.2M
Liabilities
$384.5k
Debt to equity
-0.19
CABR's short-term assets ($2.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CABR's short-term assets ($2.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CABR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CABR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$550.8k
Investing
$0.0
Financing
$395.0k
CABR vs Pharmaceutical Stocks
Caring Brands Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.